Herwenda

Herwenda is a prescription intravenous solution containing the monoclonal antibody trastuzumab. It is marketed in the European Union and supplied as a sterile liquid for infusion. The product targets the HER2 receptor and belongs to the antineoplastic class of HER2‑positive cancer therapies. The formulation is designed for use in combination with chemotherapy regimens and is indicated for patients with HER2‑positive breast or gastric advanced malignancies.

Herwenda is indicated for the treatment of cancers that overexpress the human epidermal growth factor receptor 2 (HER2).

- HER2‑positive early‑stage breast cancer as adjuvant therapy following surgery. - HER2‑positive locally advanced or metastatic breast cancer, alone or with chemotherapy. - HER2‑positive gastric or gastro‑esophageal junction adenocarcinoma in the metastatic setting. - Neoadjuvant treatment of HER2‑positive breast cancer to increase surgical resectability. - Combination therapy with taxanes or anthracyclines in HER2‑positive disease.

Adverse reactions to Herwenda have been observed in clinical practice and may vary in frequency and severity.

Common: - Fever, chills, or flu‑like symptoms during infusion. - Nausea, vomiting, or loss of appetite. - Diarrhea or abdominal pain. - Fatigue or weakness. - Headache or dizziness. - Rash or mild skin irritation.

Serious: - Cardiac dysfunction, including decreased left ventricular ejection fraction. - Severe infusion‑related reactions such as anaphylaxis or bronchospasm. - Thromboembolic events, including deep‑vein thrombosis or pulmonary embolism. - Hepatotoxicity presenting as elevated liver enzymes. - Severe neutropenia or leukopenia.

Before initiating Herwenda, clinicians should evaluate patient history and monitor specific parameters to reduce the risk of complications.

- Assess baseline cardiac function with echocardiography or MUGA scan. - Monitor left ventricular ejection fraction periodically during treatment. - Review prior hypersensitivity reactions to monoclonal antibodies or trastuzumab biosimilars. - Use caution in patients with uncontrolled hypertension or active cardiac disease. - Avoid concurrent use of anthracyclines when possible due to additive cardiotoxicity. - Adjust dosing in patients with severe hepatic impairment as recommended. - Counsel patients on signs of infusion reactions and when to seek medical attention.

Herwenda may interact with other agents that affect cardiac function or immune response, requiring careful management.

Avoid: - Concurrent anthracycline chemotherapy (e.g., doxorubicin) due to increased risk of cardiotoxicity. - Live vaccines during treatment, as immunosuppression can reduce vaccine efficacy. - High-dose corticosteroids administered immediately before infusion, which may mask early infusion reactions.

Use with caution: - Cardiotoxic drugs such as trastuzumab emtansine or other HER2‑targeted agents. - Medications that prolong QT interval, which may exacerbate cardiac monitoring concerns. - Immunosuppressive agents (e.g., azathioprine) that could increase infection risk. - Radiation therapy to the chest, which may compound cardiac stress. - Strong CYP3A4 inhibitors or inducers are not expected to affect trastuzumab but should be reviewed for overall patient safety.